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Risk factors for loss to follow-up prior to
ART initiation among patients enrolling
in HIV care with CD4+ cell count ≥200
cells/μL in the multi-country MTCT-Plus
Initiative
R Charon Gwynn1,7*, Ashraf Fawzy2, Ida Viho3, Yingfeng Wu4, Elaine J Abrams5 and Denis Nash6
Abstract
Background: In resource-limited settings, many HIV-infected patients are lost to follow-up (LTF) before starting ART;
risk factors among those not eligible for ART at enrollment into care are not well described.
Methods: We examined data from 4,278 adults (3,613 women, 665 men) enrolled in HIV care through March 2007
in the MTCT-Plus Initiative with a CD4 count ≥200 cells/mm3 and WHO stage ≤ 2 at enrollment. Patients were
considered LTF if > 12 months elapsed since their last clinic visit. Gender-specific Cox regression models were used
to assess LTF risk factors.
Results: The proportion LTF was 8.2 % at 12 months following enrollment, and was higher among women (8.4 %)
than men (7.1 %). Among women, a higher risk of LTF was associated with younger age (adjusted hazard ratio
[AHR]15–19/30+: 2.8, 95 % CI:2.1-3.6; AHR20–24/30+:1.9, 95 % CI:1.7-2.2), higher baseline CD4 count (AHR350–499/200–349:1.5; 95
% CI:1.0-2.1; AHR500+/200–349:1.5; 95 % CI:1.0-2.0), and being pregnant at the last clinic visit (AHR:1.9, 95 % CI:1.4-2.5).
Factors associated with a lower risk of LTF included, employment outside the home (AHR:0.73, 95 % CI:0.59-0.90),
co-enrollment of a family/household member (AHR:0.40, 95 % CI:0.26-0.61), and living in a household with ≥4 people
(AHR:0.74, 95 % CI:0.64-0.85). Among men, younger age (AHR15–19/30+: 2.1, 95 % CI:1.2-3.5 and AHR30–34/35+:1.5, 95 %
CI:1.0-2.4) had a higher risk of LTF. Electricity in the home (AHR:0.61, 95 % CI:0.41-0.91) and living in a household with
≥4 people (AHR:0.58, 95 % CI:0.39-0.85) had a lower risk of LTF.
Conclusions: Socio-economic status and social support may be important determinants of retention in patients not
yet eligible for ART. Among women of child-bearing age, strategies around sustaining HIV care during and after
pregnancy require attention.
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Background
Retention of patients following diagnosis and enrollment
into HIV care is a prerequisite to the optimal success of
HIV scale-up efforts, yet it remains a chronic challenge
in both resource rich and resource poor settings [1–3].
A large proportion of patients enrolling in HIV care are
in the early stages of HIV infection and not yet eligible
for anti-retroviral therapy (ART) [4]. However, little is
known about the magnitude and determinants of non-
retention among these individuals.
A large body of research demonstrating low retention
among patients that have initiated or are eligible for
ART exists [4, 5]. A review of studies from Sub Saharan
Africa found that only 70-77 % of patients on ART are
retained at the end of two years [2]. Similarly, among pa-
tients who are eligible for ART but have not yet initiated
treatment, studies also suggest high rates of non-
retention, with substantial death [6, 7] and LTF [7–9].
Growing concerns about retention through all stages of
the HIV care cascade, [4] not just among those identified
as eligible or those initiating ART, have resulted in sev-
eral recent studies that have assessed retention among
patients enrolled in HIV care but who are not yet eligible
for ART [10–13]. A review by Kranzer and colleagues
found that retention among patients ineligible for ART
ranged from 41-46 % in South Africa and was as high as
59 % in one study from Malawi [14]. Risk factors for loss
to program among patients not eligible for ART differ
from patients on ART, and have included higher initial
CD4 count, older age, male gender, pregnancy status,
longer time to clinic, and both higher and lower educa-
tion levels [10–13]. While an understanding of risk fac-
tors that may impact patient retention in this critical
stage in the HIV care cascade is growing, further exam-
ination of lost to follow- up and its risk factors among
patients not yet eligible for ART is warranted.
We assessed the magnitude and risk factors for LTF
among a population of adult men and women enrolled
in HIV care prior to ART eligibility in the multi-country
MTCT-Plus Initiative.
Methods
The MTCT-Plus Initiative provided support to clinical pro-
grams in Cameroon, Cote d’Ivoire, Kenya, Mozambique,
Rwanda, South Africa, Uganda, Zambia, and Thailand to
implement HIV/AIDS care and treatment using a family-
focused service model [15–17]. Pregnant or recently post-
partum HIV-positive women identified as HIV-infected in
PMTCT programs (index women) were enrolled and pro-
vided comprehensive HIV care including ART, if eligible
according to the current national and/or WHO guidelines
at the time of enrollment. At program entry, evaluation in-
cluded a physical examination, WHO HIV disease clinical
staging, and CD4+ cell count enumeration done at a local
laboratory. All HIV-exposed infants and HIV-infected part-
ners, family members, and children of index women were
also eligible for enrollment into the program.
Data were collected on enrolled patients from January
8, 2003 through March 31, 2008. Patients who were en-
rolled on or before March 31, 2007 were considered for
inclusion in this analysis. We identified 7,443 ART naïve
patients older than 14 years of age (6,143 women and 1,300
men) enrolled prior to March 31, 2007 at 13 MTCT-
Plus programs in 9 different countries (13 programs).
We excluded two programs (Cape Town, South Africa
and Mozambique) as data collection ended earlier (2007
and 2005, respectively) allowing less follow-up time. The
exclusion of these sites resulted in the elimination of 627
patients (653 women and 74 men). Of the remaining
6,816 patients (5,490 women and 647 men), we re-
stricted our analysis to patients who had at least 1
follow-up visit after an initial enrollment visit in order to
assess LTF among patients who engaged in HIV care be-
yond the initial enrollment visit. Additionally to assess
LTF risk factors for healthier HIV infected patients who
would be considered ineligible for ART we limited our
population to patients with a CD4 count ≥ 200 cells/
mm3 and WHO clinical stage 1 or 2 (asymptomatic to
moderately symptomatic) at enrollment. The final sam-
ple included 4,278 patients (3,613 women and 665 men).
Patients were considered LTF if their last clinic visit
was at least 12 months prior to the end of data collec-
tion and they were not known to have died, withdrawn,
transferred or initiated ART. Only patients who enrolled
at least 12 months prior to the end of data collection
were eligible to be included in the sample so that all pa-
tients had the opportunity to meet the definition for
LTF. Clinic appointments were typically scheduled 3–6
months apart based on patient's clinical status with sig-
nificant practice variability between clinics for which
specific information was not available.
Potential risk factors for LTF were examined for
women and men separately since the enrollment criteria
of the MTCT-Plus Initiative targeted pregnant or post-
partum women and all men who were either partners or
household members of index women. Univariate analysis
was conducted to identify potential risk factors for LTF.
Cox regression analysis was used to estimate the relative
hazards of LTF for each potential risk factor and in mul-
tivariable models. Patients who were known to have
died, or who withdrew, transferred, or initiated ART
were censored at the time of the event. Patients meeting
the LTF definition were considered to be lost from the
program 3 months after their last recorded clinic visit. A
robust sandwich estimate for the covariance matrix was
used to account for within site correlation [18]. Variables
that were significant at P < 0.1 in the univariate analysis
were tested in a multivariable model and those that
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remained significant with an overall P < 0.05 were
retained in the final model. If variables exhibited multi-
colinearity, only the variable with the most significant
association was retained in the model.
Enrollment year was analyzed as a categorical variable
and patients who enrolled in 2007 (3.7 % of the study
population) were grouped with those who enrolled in
2006. Pregnancy status and WHO stage were examined
at enrollment and also as time-dependent covariates.
When available, date of pregnancy provided in the clin-
ical record was used to classify women as being preg-
nant at a given clinical visit, if unavailable the data was
estimated based on the delivery date. Time-dependent
covariates were included to assess the risk of LTF associ-
ated with the most recent measurement of pregnancy
status or WHO stage. While data for CD4 tests con-
ducted after enrollment was available, CD4 count data
was not available for all patients at regular intervals
therefore we did not examine CD4 as a time-dependent
covariate. Among women, we estimated the attributable
fraction (AF) [19] and 95 % CIs of LTF associated with
pregnancy and not having adult household member
enrolled in the HIV clinic using the formula AF =
PE*(AHR-1)/[PE*(AHR-1) + 1] where AHR is the adjusted
hazard ratio for the exposure of interest, and PE is the
proportion of women with the exposure of interest.
The MTCT-Plus Initiative was approved by Columbia
University’s Institutional Review Board. Data was col-
lected for the purpose of monitoring and evaluating the
service delivery program. Relevant local ethics commit-
tees reviewed and approved the program.
Results
Table 1 shows characteristics of the study population and
proportion LTF by site. The majority of patients was fe-
male (84.5 % overall). Overall 58 (1.4 %) patients were
known to have died before initiating ART, 1,294 (30.2 %)
initiated ART and were censored, 348 (8.1 %) were docu-
mented to have withdrawn or transferred out and 1,633
(38.2 %) never initiated ART but were alive and in care at
the end of data collection. The median CD4 count at en-
rollment was 441 cells/mm3, ranging from 319 to 453
cells/mm3 across the 11 programs. The overall median
follow-up time in the program was 1.7 years, while the
proportion LTF at 12 months was 8.2 % (8.3 per 100
person-years), ranging from 0.3 % in Mulago, Uganda to
21.8 % in Kisumu Kenya. At 24 months the rate of LTF
was 15.6 %, (8.4 per 100 person-years) ranging from 1.5 %
in Mulago, Uganda to 35.9 % at Kisumu, Kenya. LTF at 12
or 24 months after enrollment was higher among women
(8.4 % and 16.0 % respectively) compared to men (7.1 %
and 13.5 % respectively). At the end of data collection
26.4 % of the total sample was LTF (26.1 % of women and
27.3 % of men) at a rate of 7.9 per 100 person-years.
Table 2 shows the characteristics of the study sample.
The median age for women was lower than that for men
(27 vs. 33 years), and the enrollment CD4 count was
higher for women than men (453 vs. 391 cells/mm3). At
baseline 1,677 (46.4 %) women were documented as
pregnant and 1,996 (55.2 %) women were pregnant at
some point during the observation period. The majority
of the patients (83.2 %) lived within 1 hour travel time
to the clinic.
In Kaplan-Meier curves (Fig. 1), women with another
family member enrolled in the program had the lowest
LTF rates over the course of follow-up (16.7 %). Higher
rates were found in index women who did not have an-
other family member enrolled (29.6 %) and men (27.3 %)
who, by definition, were a husband, partner, or house-
hold member of an index woman and therefore all had
another family member enrolled.
Factors examined for their association with LTF
among women are shown in Table 3. Younger age was
significantly associated with a higher likelihood of LTF
where women aged 15–19 and 20–24 years were more
likely to be LTF than women older than 30 years (ad-
justed hazards ratio [AHR], 2.8 95 % CI: 2.1-3.6 and 1.9,
1.7-2.2, respectively). Women with baseline CD4 count
of 350–499 and ≥ 500 cells/mm3 were 1.5 times more
likely to be LTF (95 % CI: 1.0-2.1 and 1.0-2.0 respect-
ively) than women with a CD4 count of less than 350
cells/mm. Socio-demographic indicators that were asso-
ciated with a lower likelihood of LTF included being
employed outside the home, having a family member en-
rolled in the program, and having 4 or more people in
the household (AHR: 0.73, 95 % CI: 0.59-0.90; AHR:
0.40, 0.26-0.61; and AHR: 0.74, 95 % CI: 0.64-0.85 re-
spectively). Women who were pregnant at baseline or
became pregnant during follow-up (time-dependent
variable) were more likely to become LTF than women
who did not become pregnant (AHR, 95 % CI: 1.9, 1.5-
2.5). The amount of LTF prior to ART initiation among
women attributable to pregnancy was estimated to be
33.2 % (95 % CI: 21.6 %-45.3 %), and the amount attrib-
utable to not having a family member enrolled was esti-
mated to be 8.7 % (95 % CI: 2.8 %-15.3 %).
Among men (Table 4), those aged 15–29 years were
twice as likely as those older than 35 to become LTF
(AHR, 95 % CI: 2.1, 1.2-3.5). Having electricity in the
home and living in a larger household (≥4 people) were
protective against LTF (AHR, 95 % CI: 0.61, 0.41-0.91
and 0.58, 0.39-0.85 respectively). By definition, all men
had another family member enrolled in the program
(the index woman).
Discussion
We assessed risk factors for LTF among HIV-infected,
adults enrolled in HIV-care within the MTCT-Plus
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Initiative who were not ART-eligible at enrollment. LTF
rates in our sample at 12 months after enrollment were
relatively low (8.2 %) compared with other studies in
Sub-saharan Africa [13, 14]. Among both men and women,
we found that younger age was a risk factor for LTF.
Women with higher CD4 count and those who were preg-
nant were more likely to be lost to follow-up, while having
another adult household member enrolled in the program
(a possible proxy for social support) was protective against
LTF. These findings contribute to the growing body of re-
search on outcomes among adults enrolled in HIV care
who are not yet eligible for ART [10–13].
While the population of patients in our study did not
meet ART eligibility criteria at the time the study was
conducted, most would be eligible under current WHO
recommendations which raise the CD4 threshold for
ART initiation to 500 [20, 21]. While the implementa-
tion of such guidelines in resource-limited setting may
be challenged by demand and funding constraints, a signifi-
cantly increased number of healthier patients will poten-
tially need to adhere to ART medications and routine
clinical visits. These findings suggest that less immunocom-
promised, healthier patients remain at an elevated risk for
LTF from HIV care. The logic that healthier patients are
less likely to remain in care may also hold important impli-
cations for patients enrolled in ARTat higher CD4 levels.
The higher retention rate among men than among
women has generally not been observed in other studies
of retention among pre ART patients in sub-Saharan
Africa [12, 13]. This is likely a result of the nature of the
MTCT-Plus program, which is a family-focused model
of care that recruits women and their family/household
members, including male partners. Therefore, by design,
any male in the program has at least one other female
household member enrolled with them. As a result of
this program model, risk factors for men enrolled in the
MTCT-Plus program may be different from those of
men enrolling in care independent of a partner. Mutual
support may come from disclosure of HIV status, and
may be relevant for strategies aimed at improving reten-
tion in HIV care, including among men in sub-Saharan
Africa, who generally start treatment later [22] and have
worse retention in HIV care [23, 24].
The finding that women who were pregnant at enroll-
ment or subsequent visits were at higher risk for LTF
than non-pregnant women is especially concerning. In
our study population about 55.2 % of women were either
pregnant at enrollment or at some point during follow-
up. Based on these findings we estimated that up to
33.2 % of all LTF in our study population may be attrib-
utable to pregnancy in women. Our findings are consist-
ent with at least one other recent study that
Mozambican women who were pregnant at enrollment
were 1.3 times more likely to be lost to follow-up than
those who were not pregnant, with LTF tending to occur
at or near 39 weeks gestation [13]. Similar findings have
been observed among pregnant women in South Africa
who were more likely to be LTF both prior to and fol-
lowing ART initiation [25]. Possible reasons may include
challenges of securing childcare to attend follow-up
clinic visits, undocumented transfer to other HIV care
delivery points (such as the ANC, PMTCT, or other care
and treatment sites). Given the likelihood that many
women will become pregnant at some point during their
Table 1 Site-level characteristics among patients with≥ 1 visit after enrollment with CD4≥ 200 & WHO 1 or 2 at enrollment, MTCT-Plus
Initiative, 2003-2008
Country/Site Total Females (%) Median (IQR)
FU time1,2
Deaths (%) Withdrawals3 (%) LTF at 12mo2 (%) LTF at 24mo2 (%) LTF at the end of
data collection2 (%)
Cote d' Ivoire 588 537 (91.3) 1.7 (0.7-3) 8 (1.4) 26 (4.4) 16 (3.5) 32 (8) 43 (13)
Kisumu, Kenya 304 257 (84.5) 1.5 (0.6-2.5) 7 (2.3) 11 (3.6) 58 (21.8) 89 (35.9) 105 (50.1)
Thailand 344 262 (76.2) 1.8 (0.8-2.9) 1 (0.3) 28 (8.1) 14 (4.9) 50 (20.7) 66 (33.3)
Nsambya, Uganda 387 297 (76.7) 2.1 (1.1-3.2) 4 (1) 14 (3.6) 3 (0.9) 11 (4) 22 (11.6)
Zambia 501 443 (88.4) 1.4 (0.7-2.6) 7 (1.4) 49 (9.8) 86 (19.5) 130 (32.8) 149 (45.8)
Soweto, S.A. 496 445 (89.7) 2.7 (1–3.6) 7 (1.4) 39 (8.8) 29 (6.8) 57 (14.1) 91 (26.2)
Cato Manor, S.A. 450 406 (90.2) 1.2 (0.4-2.3) 9 (2) 140 (31.1) 33 (10) 44 (14.9) 48 (19.5)
Rwanda 191 145 (75.9) 2 (1–3.4) 1 (0.5) 13 (6.8) 16 (9.5) 28 (17.9) 44 (39)
Eldoret, Kenya 286 244 (85.3) 1.8 (0.4-3.5) 1 (0.3) 2 (0.7) 17 (7.7) 25 (12) 43 (31.2)
Mulago, Uganda 331 232 (70.1) 3.1 (1.5-3.8) 9 (2.7) 11 (3.3) 1 (0.3) 4 (1.5) 6 (4)
Cameroon 400 345 (86.3) 1.2 (0.6-1.8) 4 (1) 15 (3.8) 16 (5.3) 23 (8.6) 24 (10)
Total 4278 3613 (84.5) 1.7 (0.7-3) 58 (1.4) 348 (8.1) 289 (8.2) 493 (15.6) 641 (26.4)
1In years, excluding patients with no follow-up
2Using Kaplan-Meier product limit estimation method. Patients whose last visit was > 12 months prior to the end of data collection are considered LTF. Patients
who are LTF are considered lost 90 days after their last visit
3Includes transfers
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Table 2 Baseline characteristics of patients with ≥ 1 visit after enrollment with a CD4 count ≥ 200 & WHO 1 or 2 at enrollment,
MTCT-Plus Initiative, 2003-2008
Total Women Men
Total 4278 3613 665
Age at enrollment (median, IQR) (years) 28 (24–32) 27 (23–31) 33 (29–38)
15-19 198 (4.6) 195 (5.4) 3 (0.5)
20-24 1050 (24.5) 1025 (28.4) 25 (3.8)
25-29 1361 (31.8) 1218 (33.7) 143 (21.5)
30-34 1020 (23.8) 800 (22.1) 220 (33.1)
35-39 453 (10.6) 302 (8.4) 151 (22.7)
40+ 196 (4.6) 73 (2) 123 (18.5)
CD4 at enrollment (median, IQR) (cells/uL or cells/mm3) 441 (319–608) 453 (325–620) 391 (287–522)
200-349 1352 (31.6) 1091 (30.2) 261 (39.3)
350-499 1207 (28.2) 999 (27.7) 208 (31.3)
≥500 1719 (40.2) 1523 (42.2) 196 (29.5)
WHO Stage at enrollment
I 2411 (79.7) 2905 (80.4) 506 (76.1)
II 867 (20.3) 708 (19.6) 159 (23.9)
Pregnant at enrollment - 1677 (46.4) -
≥1 Pregnancy during follow-up - 1996 (55.2) -
Disclosed HIV status 3593 (84) 2947 (81.5) 646 (97.1)
Marital Status
Legally married or living with partner 3049 (71.3) 2439 (67.5) 610 (91.7)
Not married/widowed/not living with partner 1150 (26.9) 1114 (30.8) 36 (5.4)
Education
≤8 yrs 1927 (45.5) 1668 (46.2) 259 (39)
9 - 12 yrs 1789 (41.8) 1528 (42.3) 261 (39.3)
≥13 yrs 486 (11.4) 349 (9.7) 137 (20.6)
OI Prophylaxis at enrollment 728 (17) 607 (16.8) 121 (18.2)
Employed outside home 1428 (33.4) 959 (24.5) 469 (70.5)
BMI (kg/m2)
<18.5 142 (3.3) 99 (2.7) 43 (6.5)
≥18.5 4120 (96.3) 3500 (96.9) 620 (93.2)
Electricity in the home 2636 (61.6) 2222 (61.5) 414 (62.3)
Piped water in the home 1976 (46.2) 1674 (46.3) 302 (45.4)
Adult household member enrolled at clinic - 941 (26) -
Other individuals in the household (median, IQR) 4 (3–6) 4 (3–6) 4 (3–6)
≤3 1668 (39) 1414 (39.1) 254 (38.2)
4 to 5 1315 (30.8) 1089 (30.1) 226 (34)
6 or more 1273 (29.8) 1097 (30.4) 176 (26.5)
Number of children < 5 yo in the household (median, IQR) 1 (0–1) 1 (0–1) 1 (0–1)
None 1165 (27.2) 985 (27.3) 180 (27.1)
1 or more 3014 (70.5) 2554 (70.7) 460 (69.2)
Travel time to clinic
<1 hr 3561 (83.2) 3013 (83.4) 548 (82.4)
1-2 hrs 595 (13.9) 503 (13.9) 92 (13.8)
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lifelong HIV care, and the potential for prevention of
HIV infection in newborns, HIV programs should strive
to strengthen screening, counseling, sustained outreach
and linkages to and retention in care with immediate
ART initiation. As more countries move toward immedi-
ate initiation on ART for all HIV positive pregnant
women through Option B+ 24, LTF among pregnant
women in HIV care will need to be addressed.
Our findings are consistent with qualitative studies that
have found that social support likely influences retention
in care following ART initiation [26–28]. We found that
women with a household member enrolled in the program
had the highest retention rates while women with no adult
household member enrolled had the lowest (Fig. 1). Since
all men in our study were enrolled with a family member
(the index women) the impact of partner support on re-
tention in men could not be directly assessed in our
sample. Not having another adult household member en-
rolled explained up to 8.7 % of LTF among women in our
sample. We also found that both men and women living
in larger households are more likely to stay in care, which
may also be a reflection of the influence of social support
on retention. Contrary to this finding, Lessells and col-
leagues found that women from households with 10 or
more persons were less likely to be retained in care, sug-
gesting that commitment and possibly financial con-
straints resulting from family size may result in attrition
from care [12]. Our finding that larger families enhance
retention in care may have resulted from the unique
model of care of the MTCTplus program. Social support
systems are an integral part of managing patients care
[29], and such systems can be especially helpful for pre-
ART care where the patient may not yet be experiencing
HIV-related symptoms.
Table 2 Baseline characteristics of patients with ≥ 1 visit after enrollment with a CD4 count ≥ 200 & WHO 1 or 2 at enrollment,
MTCT-Plus Initiative, 2003-2008 (Continued)
>2 hrs 111 (2.6) 88 (2.4) 23 (3.5)
Year of Enrollment
2003 834 (19.5) 690 (19.1) 144 (21.7)
2004 1744 (40.8) 1469 (40.7) 275 (41.4)
2005 989 (23.1) 847 (23.4) 142 (21.4)
2006 554 (13.0) 474 (13.1) 80 (12)
2007 157 (3.7) 133 (3.7) 24 (3.6)
Fig. 1 Kaplan Meier retention curve – by sex and adult household member enrolled in the program
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We also found that being employed outside the home
in women and having electricity in the home in men
was protective against LTF. Electricity and employment
are suggestive of higher socio-economic status, and the
resulting association indicates that there may be eco-
nomic barriers to receiving HIV care prior to eligibility
and start of ART. Even when HIV care services are free,
social or economic hardship can impact retention.
Ochieng-Ooko et al. found that socioeconomic chal-
lenges, such as work and family commitments as well as
transportation costs were important reasons for missing
clinic appointments [30]. Other studies have found that
food insecurity is a risk factor for poor retention [31, 32],
Helping patients overcome economic or financial obsta-
cles is an ongoing challenge for programs aiming to im-
prove retention, especially in pre-ART care prior to ART
Table 3 Crude and adjusted hazard ratios for key risk factors on lost to follow-up from multivariable Cox proportional hazard model:
Women
Univariate Multivariable
HR (95 % CI) P-value HR (95 % CI) P-value
Age at enrollment (years)
15-19 3 (2.2-4.2) <0.0001 2.8 (2.1-3.6) <0.0001
20-24 2.1 (1.8-2.4) <0.0001 1.9 (1.7-2.2) <0.0001
25-29 1.5 (1.2-1.7) <0.0001 1.4 (1.1-1.7) 0.0010
30+ 1.0 - 1.0 -
Pregnant at baseline 1.7 (1.2-2.4) 0.0024 - -
Pregnant (time dependent) 2.1 (1.5-2.8) <0.0001 1.9 (1.4-2.5) <0.0001
Baseline CD4 count (cells/mm3)
200-349 1.0 1.0
350-499 1.5 (1.0-2.1) 0.0486 1.5 (1.0-2.1) 0.0439
≥500 1.5 (1.1-2.2) 0.0256 1.5 (1.0-2.0) 0.0339
Baseline WHO stage
Stage I 1.0 - - -
Stage II 0.73 (0.44-1.2) 0.2213 - -
Did not disclose HIV status to partner 1.3 (0.86-1.9) 0.2364 - -
Married or living with partner 0.97 (0.83-1.1) 0.6578 - -
≥13 years of education 0.59 (0.34-1.0) 0.0.497 - -
Receiving OI prophylaxis at enrollment 0.68 (0.40-1.1) 0.1437 - -
Employed outside the home 0.63 (0.52-0.75) <0.0001 0.73 (0.59-0.90) 0.0038
BMI quartiles (kg/m2) -
≤21.9 1.0 - - -
22-24.2 1.0 (0.81-1.3) 0.8273 - -
24.3-27.2 1.1 (0.85-1.5) 0.4089 - -
27.3+ 1.0 (0.82-1.3) 0.9097 - -
Electricity inside the home 0.68 (0.49-0.93) 0.0178 - -
Tap water inside the home 0.82 (0.52-1.3) 0.4046 - -
Adult household member enrolled in the program 0.44 (0.28-0.67) 0.0002 0.40 (0.26-0.61) <0.0001
≥4 people in the household 0.67 (0.54-0.84) 0.0004 0.74 (0.64-0.85) <0.0001
At least 1 child < 5 years old in the household 0.73 (0.58-0.92) 0.0088 - -
>2 hours away from the clinic 1.0 (0.68-1.5) 0.9152 - -
Year of enrollment
2003 1.0 - - -
2004 1.3 (1.1-1.7) 0.0087 - -
2005 1.6 (1.1-2.2) 0.0091 - -
2006-2007 1.6 (0.85-3.2) 0.1348 - -
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eligibility, where clinic appointments are less frequent and
many patients may feel quite healthy.
There are important limitations that may impact inter-
pretation of our findings. First, it is possible that some
patients considered LTF may have enrolled in care at an-
other facility or service delivery point within the same
health facility (e.g., PMTCT through the ANC) during
study follow-up, but were not properly documented as
transfers (silent transfers). Given the rapid scale up of
HIV programs in resource limited settings in recent
years, it is possible that persons living further from the
clinic might seek care at a more conveniently located
facility instead of the original MTCT-Plus site. As a con-
sequence we would expect LTF to increase with travel
time to clinic and year of enrollment, as more clinical
services became readily available during the later years
of the study period. However our data did not reveal an
association between travel time and LTF or a consistent
trend with year of enrollment, as has been seen with
ART patients in large scale-up programs [33].
Similarly, some patients classified as LTF may repre-
sent unascertained deaths, potentially introducing bias
into the association between the risk factor and LTF.
This type of misclassification may also play a role in the
Table 4 Crude and adjusted hazard ratios for key risk factors on lost to follow-up from multivariable Cox proportional hazard model: Men
Univariate Multivariable
HR (95 % CI) P-value HR (95 % CI) P-value
Age at enrollment
15-29 2.4 (1.3-4.4) 0.0050 2.1 (1.2-3.5) 0.0073
30-34 1.5 (1.0-2.3) 0.0335 1.5 (1.0-2.4) 0.0468
35+ 1.0 - - -
Baseline CD4 count (cells/mm3)
200-349 1.0
350-499 1.2 (0.72-2.0) 0.4971 - -
≥500 1.7 (1.1-2.7) 0.0227 - -
Baseline WHO stage
Stage I 1.0 - -
Stage II 0.59 (0.26-1.3) 0.1996 - -
Did not disclose HIV status to partner 1.9 (0.59-6.4) 0.2721 - -
Married or living with partner 0.99 (0.41-2.4) 0.9739 - -
≥13 years of education 0.53 (0.34-0.84) 0.0069 - -
Receiving OI prophylaxis at enrollment 0.81 (0.43-1.5) 0.5056 - -
Employed outside the home 0.66 (0.36-1.2) 0.1735 - -
BMI quartiles -
<20.2 1.0 - - -
20.3-21.9 1.0 (0.71-1.5) 0.8412 - -
22-24.2 0.58 (0.32-1.1) 0.0744 - -
24.3+ 0.76 (0.45-1.3) 0.3201 - -
Electricity inside the home 0.65 (0.39-1.1) 0.0883 0.61 (0.41-0.91) 0.0158
Tap water inside the home 1.0 (0.51-2.0) 0.9792 - -
≥4 people in the household 0.48 (0.32-0.71) 0.0002 0.58 (0.39-0.85) 0.0053
At least 1 child < 5 years old in the household 0.77 (0.51-1.2) 0.2151 - -
>2 hours away from the clinic 1.3 (0.51-3.1) 0.6191 - -
Year of enrollment
2003 1.0 - - -
2004 1.0 (0.57-1.8) 0.9943 - -
2005 1.3 (0.74-2.1) 0.3940 - -
2006-2007 1.1 (0.41-2.7) 0.8960 - -
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finding that pregnant women are more likely to be lost
to follow-up, as maternal mortality is substantial in sub-
Saharan Africa where 1 in 31 women die during child-
birth (ranging from 470–930 deaths per 100,000 live
births) [34]. Geng et al. suggest that true causal relation-
ship can be assessed through ascertainment of patients
status who are lost to follow-up, using a sampling based
approach and adjustment of estimates [24]. However,
while misclassification of HIV-related deaths as LTF is a
possibility, this may be less of a concern in our study
population, which was limited to those with CD4 ≥ 200
and WHO stage I or II at baseline. Additionally, our def-
inition of LTF may not accurately categorize patients
who leave care for a prolonged period but then return to
care and should be considered LTF. This misclassifica-
tion is likely minimal as the median time between visits
was 56 days, and only 237 (5 %) of patients who were
considered to be retained in care had 12 month or lon-
ger lapses between prior clinic visits, suggesting that
most patients with lengthy lapses are in fact LTF.
Another important limitation is the generalizability of
the findings to general HIV care populations. Specific-
ally, males in the study were closely related to an index
women already enrolled in the program (either as a hus-
band, partner or household member) and are not repre-
sentative of the general population as they all have had
the index woman’s HIV status disclosed to them and
have subsequently agreed to HIV testing and enrollment
into HIV care. Additionally, the focus of this study is pa-
tients who have initially engaged in HIV care, by attend-
ing at least one visit, and generalization to the entire
HIV-infected population accessing care should be
cautioned.
Finally, we observed variations in LTF by site (Table 1).
Standardized protocols developed for the MTCT-Plus
Study were implemented across the study facilities; how-
ever there may have been some differences in the way
that facilities implemented the protocols. Such differ-
ences were not systematically documented, and could
not be accounted for in or explained by this analysis.
Conclusions
Retention in HIV care prior to ART initiation is a pre-
requisite to: 1) optimal prophylaxis, diagnosis, and treat-
ment of opportunistic illnesses; 2) effective secondary
prevention of HIV transmission; and 3) more timely
ART initiation. This study provides insights into risk fac-
tors for LTF among patients enrolled in care with CD4 ≥
200 cells/μL and WHO stage ≤ 2 at enrollment who were
not yet on ART in the family-focused MTCT-Plus Initia-
tive. Socio-demographic and social support factors were
protective against LTF in both men and women; our
findings suggest that both groups may benefit substan-
tially from enrolling with a family or other household
member that they feel comfortable enough to disclose
to. Overcoming broad barriers to care associated with
lower SES and lack of social support will likely remain a
challenge to care and treatment programs. However
gender-specific risk factors also compromise program
retention, of particular importance is the risk of LTF
among pregnant women enrolled in HIV care. Among
women of child-bearing age, counseling and strategies
around sustaining continuity of HIV care during and after
the pregnancy and engagement in ART and PMTCT are
particularly important. Retaining healthier patients in care
and ART is critical to minimizing HIV morbidity and re-
ducing HIV transmission, effective strategies must be de-
veloped that are customized to the needs of the patient
population.
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